03/06/2019 Amgen Italia, Centro Studi Italian Biosimilars Group, Fabio Pammolli, farmaci biosimilari, Italian Health Policy Brief, Maria Luce Vegna, Maria Teresa Bressi, Simona Creazzola, www.amgen.it